A Phase 1 interventional study of BBC1501 in Age-Related Macular Degeneration, sponsored by Benobio Co., Ltd.. Recruiting at 2 sites in Australia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Benobio Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Macular Degeneration with a site in Australia — 17 open to participants now, 22 under way, 7 of them phase 3. Macular Degeneration · Australia.
Among the 77 studies in Macular Degeneration with a site in Australia, this one is the 61st largest by planned enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2025, is one of 5 in phase 1, reaches primary completion later than 1 of the 21 other live ones, and was the 60th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →17 of the 77 studies in Macular Degeneration with a site in Australia are open now. Recruiting first, the newest first:
Biojiva LLC · Sites in Australia, United States
Ages 55+
Sitala Bio LTD · Sites in Australia, United States, Argentina and 4 more countries
Ages 60+
EyeBiotech Ltd. · Sites in Australia, United States, Argentina and 9 more countries
Ages 50+
Novartis Pharmaceuticals · Sites in Australia, United States, Argentina and 16 more countries
Ages 50+
ADARx Pharmaceuticals, Inc. · Sites in Australia, United States, Austria and 9 more countries
Ages 60+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 26 · Phase 3 26 · Phase 4 6
First in 2003; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 280 across the 66 interventional studies, 400 across the 11 observational. Of the 54 that completed or were terminated, 30 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 77 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Benobio Co., Ltd. as lead sponsor.
Benobio Co., Ltd. has 1 study filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
9 of the studies in Macular Degeneration with a site in Australia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06495918Phase 3Ocular Therapeutix, Inc.Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | 2027-01-08 |
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT07064759Phase 34D Molecular TherapeuticsSingle Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-11 |
| NCT05803785Benobio Co., Ltd.Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD) | 2026-12 |
| NCT07766473Filamon LTDFirst in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD) | 2027-03 |
Add all 9 to your calendar (.ics) → With an account.
Among the 77 studies in Macular Degeneration with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This open-label study is being conducted to evaluate the initial safety and tolerability of BBC1501 IVT in patients with nAMD. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of IVT BBC1501 in patients with nAMD. The secondary objective of this study is to exploratory of BBC1501 efficacy following 3 ascending dose of BBC1501 in nAMD patient.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1; open-label, non-randomized, single administration
Drug: BBC1501
Cohort 2; open-label, non-randomized, single administration
Drug: BBC1501
Cohort 3; open-label, non-randomized, single administration
Drug: BBC1501
BBC1501 solution for Intravitreal injection
Assessment of ophthalmic and systemic TEAEs, during study period
To evaluate the safety and tolerability of a single IVT dose of BBC1501 at 4 weeks after dose.To characterize ocular and non-ocular safety by the incidence of treatment-emergent adverse events (AEs) (new or worsening from baseline) summarized categorically by system organ class and/or preferred term.
Time frame: Every week up to 4 weeks
Assessment of ophthalmic and systemic TEAEs, during study period
To evaluate the safety and tolerability of a single IVT dose of BBC1501 at 12 weeks after dose.To characterize ocular and non-ocular safety by the incidence of treatment-emergent adverse events (AEs) (new or worsening from baseline) summarized categorically by system organ class and/or preferred term.
Time frame: every 4 weeks up to 12 weeks
Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA from baseline
Assessment ETDRS change from baseline by Optical Coherence Tomography(OCT)
Time frame: Baseline, Week4
Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA from baseline
Assessment ETDRS change from baseline by Optical Coherence Tomography(OCT)
Time frame: Baseline, Week12
Number of patients who initiation of rescue therapy during study
Exploratory using rescue therapy during study and follow-up period
Time frame: Week1, Week12
Change in CNV size according to fluorescein angiogram
Assessment CNV size change from baseline by Fundus fluorescein angiography(FFA)
Time frame: Baseline, Week4
Change in CNV size according to fluorescein angiogram
Assessment CNV size change from baseline by Fundus fluorescein angiography(FFA)
Time frame: Baseline, Week12
Changes in intra-or sub-retinal fluid measured as mean change in central retinal thickness or macula volume
Assessment Central retinal thickness from baseline by Spectral Domain Optical Coherence Tomography (SD-OCT)
Time frame: Baseline, Week4
Changes in intra-or sub-retinal fluid measured as mean change in central retinal thickness or macula volume
Assessment Central retinal thickness from baseline by Spectral Domain Optical Coherence Tomography (SD-OCT)
Time frame: Baseline, Week12
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's planned 17 months is above that.
Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.